SARC045 Opens to Enrollment

SARC is excited to announce that SARC045 is now open and actively recruiting patients in the United States and (shortly) the United Kingdom. This Phase II trial is investigating tebentafusp in HLA-A*02:01-positive adults with advanced clear cell sarcoma (CCS).

This promising study, co-led by Drs. Sandra D’Angelo (Memorial Sloan Kettering Cancer Center) and Andrea Napolitano (The Royal Marsden Hospital), include the following sites:

• Memorial Sloan Kettering Cancer Center, New York, NY, USA (currently open to enrollment)
• The Royal Marsden Hospital, London, UK (opening soon)
• Two additional sites in the USA (Chicago, IL & Los Angeles, CA) are planned to open to enrollment over the next several months

Notably, SARC “embeds” patient advocates into our sponsored trials, thus integrating the patient perspective to ensure that our research reflects the real-world needs and experiences of those living with sarcoma. For SARC045, SARC is grateful to the Clear Cell Sarcoma Foundation for their help in identifying the CCS advocate.